Detailed explanation of the role and efficacy of bosutinib/bosutinib

Bosutinib/Bosutinib is a small molecule tyrosine kinase inhibitor mainly used to treat chronic myelogenous leukemia (CML). Its mechanism of action is mainly by inhibiting the kinase activity of BCR-ABL fusion protein, thereby preventing the proliferation and growth of tumor cells. The production of BCR-ABL kinase is closely associated with the development of chronic myelogenous leukemia, so the targeting of bosutinib makes it an effective treatment option.

In addition to inhibitingBCR-ABL kinase, bosutinib can also affect other kinases of the Src family, such as Src, Lyn and Hck. These kinases play an important role in cell signal transduction and are involved in regulating cell growth and survival. By inhibiting multiple kinases simultaneously, bosutinib may improve treatment efficacy and have a broader impact on drug-resistant leukemia cells.

Clinical studies have shown that bosutinib can still exert a certain effect on patients who are resistant to traditional treatments such as imatinib. Specifically, bosutinib inhibits 16 of the 18 BCR-ABL kinase mutations associated with imatinib resistance. This property makes bosutinib an important treatment option when faced with drug-resistant cases. However, it should be noted that bosutinib does not exhibit inhibitory effects on T315I and V299L mutant cells, which limits its application in patients with certain drug-resistant types of leukemia.

In terms of drug safety, studies have shown that there is a positive correlation between bosutinib exposure and treatment response, that is, the higher the exposure, the greater the likelihood of response, but it also increases the risk of adverse reactions. Therefore, during the treatment process, doctors need to make reasonable adjustments to the dosage to balance efficacy and safety.

In addition, the pharmacokinetic characteristics of bosutinib also deserve attention. The study pointed out that when a single oral dose of 500 mg bosutinib was used together with the potent CYP3A inhibitor ketoconazole, bosutinib did not significantly prolong the QT interval, suggesting that it has certain advantages in terms of cardiac safety.

Reference materials:https://go.drugbank.com/drugs/DB06616